Edition:
United Kingdom

Nanobiotix SA (NANOB.PA)

NANOB.PA on Paris Stock Exchange

12.60EUR
1:48pm GMT
Change (% chg)

€0.43 (+3.53%)
Prev Close
€12.17
Open
€12.29
Day's High
€12.69
Day's Low
€12.17
Volume
59,589
Avg. Vol
132,784
52-wk High
€18.87
52-wk Low
€8.30

Latest Key Developments (Source: Significant Developments)

Nanobiotix: Positive Phase II/III Results For NBTXR3 In Soft Tissue Sarcoma
Friday, 19 Oct 2018 

Oct 19 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX: POSITIVE PHASE II/III RESULTS FOR NBTXR3 IN SOFT TISSUE SARCOMA PRESENTED AT ESMO.NBTXR3 IS FIRST RADIOTHERAPY ENHANCER TO DEMONSTRATE CLINICALLY MEANINGFUL BENEFIT FOR PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA COMPARED TO RADIOTHERAPY ALONE.NBTXR3 IS FIRST RADIOTHERAPY ENHANCER TO DEMONSTRATE CLINICALLY MEANINGFUL BENEFIT FOR PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA COMPARED TO RADIOTHERAPY ALONE.PRIMARY AND MAIN SECONDARY ENDPOINTS WERE MET.IN SUBGROUP OF PATIENTS HAVING AN ADVANCED DISEASE, 4-TIMES MORE PATIENTS ACHIEVED A PATHOLOGICAL COMPLETE RESPONSE IN NBTXR3 ARM COMPARED TO CONTROL ARM.NBTXR3 SHOWED A GOOD LOCAL TOLERANCE AND NO IMPACT ON SEVERITY OR INCIDENCE OF RADIOTHERAPY-RELATED ADVERSE EVENTS.  Full Article

Nanobiotix H1 Operating Loss 13.0 Million Euros
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - NANOBIOTIX SA ::H1 TOTAL REVENUE EUR 2.1 MILLION VERSUS EUR 1.9 MILLION YEAR AGO.H1 OPERATING LOSS EUR 13.0 MILLION VERSUS LOSS OF EUR 11.8 MILLION YEAR AGO.H1 LOSS EUR 12.6 MILLION VERSUS LOSS OF EUR 12.2 MILLION YEAR AGO.SAYS CASH POSITION AT THE END OF JUNE ENABLES US TO SECURE OUR GROWTH BEYOND 2019.GROUP HAD CASH AND CASH EQUIVALENTS AT JUNE 30, 2018 OF €32.7 M (31 DECEMBER 2017: €47.2M).  Full Article

Nanobiotix Q2 2018 Revenue EUR 73K, Fully In Line With Its Expectations
Thursday, 12 Jul 2018 

July 12 (Reuters) - Nanobiotix SA ::COMPANY GENERATED €73K DURING THE SECOND QUARTER OF 2018, WHICH IS FULLY IN LINE WITH THE COMPANY’S EXPECTATIONS..CURRENTLY, THE COMPANY IS EVALUATING NBTXR3 IN SEVEN CLINICAL TRIALS WITH A FOCUS ON HEAD AND NECK CANCERS AND IMMUNO-ONCOLOGY PROGRAMS.Q2 REVENUE EUR 73,304 VERSUS EUR 58,499 YEAR AGO.  Full Article

Nanobiotix Did Not Generate Any Revenue In Q1
Wednesday, 16 May 2018 

May 16 (Reuters) - NANOBIOTIX SA ::ANNOUNCED ON TUESDAY IT DID NOT GENERATE ANY REVENUE FOR Q1 2018, AS IT HAD EXPECTED.  Full Article

Nanobiotix Partners With The Providence Cancer Institute To Run Immunotherapeutic Preclinical Research In Pancreatic Cancers
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX PARTNERS WITH THE PROVIDENCE CANCER INSTITUTE TO RUN IMMUNOTHERAPEUTIC PRECLINICAL RESEARCH IN PANCREATIC CANCERS.COLLABORATION WILL TAKE PLACE OVER COURSE OF ONE YEAR.WILL LAUNCH ITS FIRST CLINICAL TRIAL COMBINING NBTXR3 WITH IMMUNE CHECKPOINT INHIBITORS IN U.S..HAS RECEIVED APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND.  Full Article

Nanobiotix Q3 revenue down at 33.0‍​ million euros
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - NANOBIOTIX SA ::Q3 REVENUE EUR 33.0‍​ MILLION VERSUS EUR 58.6 MILLION YEAR AGO.  Full Article

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology
Monday, 13 Nov 2017 

Nov 13 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX PRESENTED NEW CLINICAL AND PRE-CLINICAL DATA CONFIRMING NBTXR3'S SIGNIFICANT POTENTIAL ROLE IN IMMUNO-ONCOLOGY AT SITC ANNUAL MEETING.‍PATIENTS TREATED WITH NBTXR3 AND RADIOTHERAPY SHOW A MARKED INCREASE OF PD1 AND CD8 INFILTRATION​.‍NBTXR3 ACTIVATED BY RADIOTHERAPY INDUCES SIGNIFICANT ADAPTIVE IMMUNE PATTERN VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH SOFT TISSUE SARCOMA​.‍STRONG DATA TO SUPPORT RATIONAL FOR UPCOMING CLINICAL TRIAL IN COMBINATION WITH CHECK POINT INHIBITORS​.‍PRECLINICAL DATA ON DIFFERENT ANIMAL MODELS CONFIRM BROAD POTENTIAL OF NBTXR3 AS A PRIMER OF IMMUNE RESPONSE​.  Full Article

Nanobiotix completes new share issue for about 27.2 million euros
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX SUCCESSFULLY COMPLETES APPROXIMATELY EUR 27.2 MILLION PLACEMENT OF NEW SHARES.‍ISSUES OF 1,941,789 NEW SHARES, PAR VALUE EUR 0.03​.‍ISSUE PRICE OF NEW SHARES HAS BEEN SET AT EUR 14.00 PER SHARE, REPRESENTING AN 18% DISCOUNT​.‍TRADING OF THE NEW SHARES TO START ON EURONEXT PARIS ON NOVEMBER 2, 2017​.  Full Article

Nanobiotix completes patient inclusion for phase II/III trial of NBTXR3
Monday, 23 Oct 2017 

Oct 23 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX COMPLETES PATIENT INCLUSION FOR PHASE II/III TRIAL OF NBTXR3 IN SOFT TISSUE SARCOMA.‍LAST PATIENTS ARE EXPECTED TO START TREATMENT IN TWO TO THREE WEEKS​.‍EXPECTS TO PRESENT RESULTS OF ITS PHASE II/III TRIAL IN SOFT TISSUE SARCOMA IN FIRST HALF OF 2018​.  Full Article

French and Benelux stocks-Factors to watch on July 13

July 13 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.